Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04320888
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:02.988761+00:00
Published At
2025-11-06T00:00:00+00:00
Record Updated At
2026-04-24
Results Posted At
2025-11-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hematopoietic and Lymphatic System Neoplasm", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent WHO Grade 2 Glioma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Histiocytic and Dendritic Cell Neoplasm", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Refractory WHO Grade 2 Glioma", "Wilms Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-24"
protocolSection.identificationModule.nctId
"NCT04320888"
protocolSection.identificationModule.officialTitle
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-11-06"

Study condition terms

  • Hematopoietic and Lymphatic System Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Ependymoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ewing Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Histiocytic and Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Recurrent Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Germ Cell Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Glioma (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent WHO Grade 2 Glioma (protocolSection.conditionsModule.conditions)
  • Refractory Ependymoma (protocolSection.conditionsModule.conditions)
  • Refractory Ewing Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Histiocytic and Dendritic Cell Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Refractory Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Germ Cell Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Glioma (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory WHO Grade 2 Glioma (protocolSection.conditionsModule.conditions)
  • Wilms Tumor (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.